Dipyridamole

Sold as Persantine, Iv Persantine. Every FDA application for this active ingredient: 2 branded and 24 generic.

As of Nov 15, 2026, FDA lists 26 applications for Dipyridamole (sold as Persantine, Iv Persantine), first approved Dec 6, 1961, with 1 new use approved and 0 published complete response letters.

First approved: Dec 6, 1961
Applications: 26
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $1.1M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Dipyridamole	Part D	$1.0M	-21%	2,585
Dipyridamole	Part B	$45K	-55%	2,434

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

DIPYRIDAMOLE 25 MG TABLET: $0.131 per unitGeneric · -37% in a year
DIPYRIDAMOLE 50 MG TABLET: $0.323 per unitGeneric · +2% in a year
DIPYRIDAMOLE 75 MG TABLET: $0.285 per unitGeneric · -10% in a year

Clinical Trials

12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Non-Invasive Coronary Functional Evaluation of Patients With Single-vessel Coronary Artery DiseasePCI Patients, Single Coronary Vessel Disease · Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Not applicable	Not yet recruiting	Sep 4, 2026
Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological EffectsPreeclampsia (PE), Hypertension ,Pregnancy · Hadassah Medical Organization	Phase 1 / Phase 2	Not yet recruiting	Jul 31, 2026
Non-invasive Evaluation of Patients With Angina and Non-obstructive Coronary Artery DiseaseANOCA - Angina With Non-obstructive Coronary Arteries · Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Not applicable	Not yet recruiting	Feb 20, 2026
A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With DipyridamoleRestless Leg Syndrome Due to Uraemia · Yunfeng Xia	Phase 2 / Phase 3	Recruiting	Sep 30, 2025
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale StudyIschemic Stroke, Patent Foramen Ovale · National University Hospital, Singapore	—	Not yet recruiting	May 21, 2025
Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery StenosisAsymptomatic Carotid Artery Stenosis · Beijing Tiantan Hospital	Not applicable	Recruiting	Mar 28, 2025
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant RecipientsHypophosphatemia, Kidney Transplantation · Stanford University	Phase 2	Recruiting	Feb 13, 2025
Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTACoronary Artery Disease, Coronary Computed Tomography Angiography · Semmelweis University	Not applicable	Recruiting	Nov 1, 2024

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Dec 6, 1961	PersantineNDA 12836 · New molecular entity	Boehringer Ingelheim	22	Discontinued
Sep 29, 1980	DipyridamoleANDA 87184	Barr	28	Marketed
Oct 3, 1990	DipyridamoleANDA 87716	Barr	23	Marketed
Oct 3, 1990	DipyridamoleANDA 87717	Barr Labs	20	Marketed
Dec 13, 1990	Iv PersantineNDA 19817 · New dosage form	Boehringer Ingelheim	13	Discontinued
Feb 5, 1991	DipyridamoleANDA 88999	Glenmark Generics	13	Discontinued
Feb 5, 1991	DipyridamoleANDA 89000	Glenmark Generics	13	Discontinued
Feb 5, 1991	DipyridamoleANDA 89001	Glenmark Generics	12	Discontinued
Apr 16, 1991	DipyridamoleANDA 86944	Ani Pharms	19	Discontinued
Feb 25, 1992	DipyridamoleANDA 87561	Idt Australia Ltd	1	Discontinued
Feb 25, 1992	DipyridamoleANDA 87562	Idt Australia Ltd	1	Discontinued
Jun 7, 1996	DipyridamoleANDA 87160	Watson Labs	31	Discontinued
Oct 18, 1996	DipyridamoleANDA 74521	Hikma	8	Marketed
Nov 26, 1997	DipyridamoleANDA 74952	Dr Reddys	0	Discontinued
Dec 19, 1997	DipyridamoleANDA 74601	Hospira	7	Discontinued
Apr 13, 1998	DipyridamoleANDA 74939	Chartwell Injectable	1	Marketed
Sep 30, 1998	DipyridamoleANDA 74956	Fresenius Kabi USA	3	Discontinued
Jan 3, 2000	DipyridamoleANDA 89427	Purepac Pharm	0	Discontinued
Nov 27, 2002	DipyridamoleANDA 75769	Eugia Pharma Speclts	0	Discontinued
Apr 21, 2006	DipyridamoleANDA 40542	Oxford Pharms	0	Marketed
Feb 13, 2007	DipyridamoleANDA 40733	Rising	2	Marketed
Jul 18, 2007	DipyridamoleANDA 40782	Impax Labs	1	Marketed
Jan 28, 2008	DipyridamoleANDA 40874	Zydus Pharms USA Inc	2	Marketed
Apr 23, 2008	DipyridamoleANDA 40898	Chartwell Rx	0	Discontinued
—	DipyridamoleANDA 89425	Purepac Pharm	0	Discontinued
—	DipyridamoleANDA 89426	Purepac Pharm	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA